SOPHiA GENETICS SA - 20-F Filing Summary
Business Context and Reporting Period
Company: SOPHiA GENETICS SA (Nasdaq: SOPH)
Reporting Period: Fiscal Year Ended December 31, 2025
Business Overview: A cloud-native software technology company providing the SOPHiA DDM Platform for data-driven medicine. The platform analyzes multimodal data (genomics, radiomics, clinical) to support precision medicine in oncology, rare diseases, and other areas. The company operates globally with a decentralized model, serving hospitals, laboratories, and biopharmaceutical companies.
Accounting Basis: International Financial Reporting Standards (IFRS).
Key Financial Metrics
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Revenue | $77.3 million | $65.2 million | +19% |
| Gross Profit | $52.1 million | $43.9 million | +19% |
| Gross Margin | 67% | 67% | Stable |
| Net Loss | $(79.0) million | $(62.5) million | Widened |
| Operating Loss | $(70.9) million | $(66.6) million | Widened |
| Cash and Cash Equivalents | $70.3 million | $80.2 million | Decreased |
| Debt Outstanding | $50.0 million | $15.0 million | Increased |
| Accumulated Deficit | $(519.3) million | $(440.3) million | N/A |
Key Operational Metrics:
- Platform Analysis Volume: 391,698 (2025) vs. 352,628 (2024), an 11% increase.
- Core Genomics Customers: 528 (2025) vs. 472 (2024).
- Net Dollar Retention (NDR): 115% (2025) vs. 104% (2024).
- Revenue Churn: 0.1%.
Material Changes vs. Prior Period
- Revenue Growth: Driven by a 11% increase in analysis volume, particularly in Hematological Oncology (HemOnc) applications, and strong growth in EMEA and North America (NORAM). Foreign exchange appreciation of the Euro contributed approximately $2.0 million to revenue.
- Increased Expenses:
- General & Administrative (G&A): Increased by $5.6 million (12%), primarily due to $2.4 million in legal expenses related to Guardant Health litigation and costs associated with shelf registration/ATM programs.
- Selling & Marketing: Increased by $6.7 million (23%) due to sales force expansion and higher commissions.
- Interest Expense: Increased by $2.6 million (138%) following the drawdown of a second $35.0 million tranche of term loans in June 2025.
- Foreign Exchange Impact: The company recorded a net foreign exchange loss of $3.4 million in 2025, compared to a gain of $3.5 million in 2024, driven by the revaluation of intercompany receivables.
- Tariff Exposure: New U.S. tariffs on Swiss imports (initially 31%, adjusted to 15% retroactively) increased costs of revenue for U.S. bundle sales, though the company expects to offset some costs via price increases.
Guidance, Outlook, and Risks
Outlook: Management expects to continue incurring net losses for the foreseeable future as it invests in R&D, sales expansion, and regulatory approvals. The company believes its current cash position ($70.3 million) plus access to additional credit facilities is sufficient for at least the next 12 months.
Recent Developments:
- Guardant Health Litigation: In January 2026, the Unified Patent Court (UPC) rejected Guardant's application for provisional measures and ordered Guardant to pay an interim costs award of €400,000. Guardant has appealed. The company expects to receive this payment by March 10, 2026. U.K. proceedings remain pending.
- Debt Facility Amendment: In January 2026, the company amended its credit agreement to add $25.0 million in additional term loan commitments (Tranches C and D), contingent on revenue milestones.
- Leadership Transition: CEO Jurgi Camblong is set to become Executive Chairman, with President Ross Muken becoming CEO effective July 1, 2026.
Key Risks:
- Regulatory: Products in the U.S. are currently labeled "Research Use Only" (RUO). Future commercialization as In Vitro Diagnostics (IVD) requires FDA clearance, which is uncertain and costly.
- Intellectual Property: Ongoing patent infringement litigation with Guardant Health poses a risk of injunctions or damages in the U.K. and EU.
- Profitability: The company has an accumulated deficit of $519.3 million and expects continued losses.
- Third-Party Reliance: Heavy reliance on Microsoft Azure for cloud infrastructure and third-party manufacturers for consumables.
Investor Verification Checklist
- Profitability Path: Verify the timeline and cost assumptions for achieving cash flow positivity, given the widening net loss and high R&D/S&M spend.
- Guardant Litigation Outcome: Monitor the appeal process and U.K. proceedings for potential injunctions that could block sales in key markets.
- Regulatory Strategy: Assess progress on FDA 510(k) or PMA submissions for IVD status, which is critical for U.S. clinical revenue expansion.
- Tariff Impact: Confirm the extent to which U.S. tariffs on Swiss imports are being passed through to customers versus absorbed in margins.
- Debt Covenants: Review compliance with the Perceptive Credit Agreement covenants, specifically the $67.4 million trailing twelve-month revenue covenant.